The increased knowledge of overlapping biological processes that contribute to both NAFLD and alcohol-associated/related liver disease (ALD), coupled with the increased clinical and public relevance of this dual etiology, has led to a recent effort across multiple international liver societies to develop a new nomenclature
Even as this approach gains popularity, pharmaceutical companies advise patients against adjusting dosages
If you found this article helpful, dont forget to like , share , and Follow to stay up to date on our latest health tips, pharmacy updates, and wellness advice
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus (Mounjaro) and chronic weight management (Zepbound)
While regulatory reviews have not established a causal link, monitoring is advised